Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2009 1
2010 6
2011 23
2012 61
2013 70
2014 107
2015 123
2016 138
2017 138
2018 191
2019 171
2020 143
2021 162
2022 155
2023 152
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

1,486 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Castellino SM, et al. N Engl J Med. 2022 Nov 3;387(18):1649-1660. doi: 10.1056/NEJMoa2206660. N Engl J Med. 2022. PMID: 36322844 Free PMC article. Clinical Trial.
The percentage of patients who received involved-site radiation therapy did not differ substantially between the brentuximab vedotin group and the standard-care group (53.4% and 56.8%, respectively). ...Overall survival at 3 years was 99.3% (95% CI, 97.3 to 99.8) in …
The percentage of patients who received involved-site radiation therapy did not differ substantially between the brentuximab vedot …
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma. ...FINDINGS: Between July 8, 2016, and July 13, 2018, 151 patients were randomly assigned to pembr …
Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed …
Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Van Der Weyden C, et al. Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18. Expert Rev Hematol. 2019. PMID: 30526166 Review.
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. ...Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-ce …
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting a …
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Ansell SM, et al. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13. N Engl J Med. 2022. PMID: 35830649 Clinical Trial.
BACKGROUND: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed antibody-drug con …
BACKGROUND: Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed lo …
Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE, Egress ER, Lowe EJ. Agrusa JE, et al. Front Immunol. 2023 May 18;14:1203471. doi: 10.3389/fimmu.2023.1203471. eCollection 2023. Front Immunol. 2023. PMID: 37275877 Free PMC article. Review.
Brentuximab vedotin is well-tolerated in both the pediatric and adult populations, even when used in combination with conventional agents. Brentuximab vedotin is an ideal agent to treat ALCL with excellent targeted activity and limited toxicity. ...
Brentuximab vedotin is well-tolerated in both the pediatric and adult populations, even when used in combination with conventi …
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Horwitz SM, et al. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Blood Adv. 2021. PMID: 34507350 Free PMC article. Clinical Trial.

Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative effects on quality of life. ...Median PFS with brentuximab vedotin vs physician's choice was 16.7 months vs 3.5 months (P < .

…
Cutaneous T-cell lymphomas often cause pruritus and pain; brentuximab vedotin improved skin symptom burden with no negative ef …
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). ...
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients wi …
Brentuximab vedotin.
[No authors listed] [No authors listed] Drugs R D. 2011;11(1):85-95. doi: 10.2165/11591070-000000000-00000. Drugs R D. 2011. PMID: 21410298 Free PMC article. Review.
Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company. ...
Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genet …
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.
Nivolumab dose reduction was not allowed. Brentuximab vedotin dose reduction to 1.2 mg/kg was permitted. If one drug was discontinued because of a toxic effect, the other could be continued. ...No treatment-related deaths were observed. INTERPRETATION: Brentuxima …
Nivolumab dose reduction was not allowed. Brentuximab vedotin dose reduction to 1.2 mg/kg was permitted. If one drug was disco …
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Prince HM, et al. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. Lancet. 2017. PMID: 28600132
Grade 3-4 adverse events were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients in the physician's choice group. ...INTERPRETATION: Significant improvement in objective response lasting at least 4 months was seen with …
Grade 3-4 adverse events were reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients …
1,486 results